Dispenzieri, A <br/><br/>
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.  [electronic resource] 

 -  Leukemia  12 2017 
 - 2791-2798 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2017.120  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Drug Resistance, Neoplasm<br/>Female<br/>Genetic Engineering<br/>Genetic Therapy--adverse effects<br/>Genetic Vectors--administration & dosage<br/>Humans<br/>Male<br/>Measles virus--genetics<br/>Mice<br/>Middle Aged<br/>Multiple Myeloma--diagnosis<br/>Oncolytic Virotherapy--adverse effects<br/>Oncolytic Viruses--genetics<br/>Recurrence<br/>Single Photon Emission Computed Tomography Computed Tomography<br/>Symporters--genetics<br/>Tissue Distribution<br/>Treatment Outcome<br/>Xenograft Model Antitumor Assays